Revolution Medicines, Inc. (RVMD)

37,11 +1,15 (+3,20%) Börsenschluss: 04:00PM EDT

Revolution Medicines, Inc.

700 Saginaw Drive
Redwood City, CA 94063
United States
650 481 6801
https://www.revmed.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 378

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Mark A. Goldsmith Ph.D.	CEO, President & Chairman	1,12M	2,85M	1962
Mr. Jack Anders	Chief Financial Officer	665,28k	1,02M	1977
Ms. Margaret A. Horn J.D.	Chief Operating Officer	811,08k	1,68M	1963
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.	President of Research & Development	812,17k	N/A	1961
Ms. Xiaolin Wang	Executive Vice President of Development	633,74k	N/A	1971
Dr. Martin D. Burke M.D., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Dr. Michael A. Fischbach Ph.D.	Academic Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1981
Dr. Kevan M. Shokat Ph.D.	Academic Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Walter Reiher Ph.D.	Chief Information Officer	N/A	N/A	N/A
Ms. Jan Smith Ph.D.	Chief Scientific Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Corporate Governance

Revolution Medicines, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 7. Die grundlegenden Scores sind Audit: 3, Vorstand: 8, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.